Relugolix in heavy menstrual bleeding associated with uterine fibroids

Phase 3, randomised, double-blind trial of tissue-plasminogen activator in Heavy menstrual bleeding and Uterine Fibroids (UF) (2 arms), sponsored by Qilu Pharmaceutical. Primary endpoint: Percentage of participants who achieved a menstrual blood loss volume of <80 mL and ≥50% reduction from baseline menstrual blood loss volume at 12 weeks. Started Jan 2024; status: recruiting.